These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 36544382

  • 1. The use of 68 Ga-PSMA PET/CT to stratify patients with PI-RADS 3 lesions according to clinically significant prostate cancer risk.
    Yang J, Tang Y, Zhou C, Zhou M, Li J, Hu S.
    Prostate; 2023 Apr; 83(5):430-439. PubMed ID: 36544382
    [Abstract] [Full Text] [Related]

  • 2. 68Ga-PSMA PET/CT-based multivariate model for highly accurate and noninvasive diagnosis of clinically significant prostate cancer in the PSA gray zone.
    Yang J, Li J, Xiao L, Zhou M, Fang Z, Cai Y, Tang Y, Hu S.
    Cancer Imaging; 2023 Sep 04; 23(1):81. PubMed ID: 37667341
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combined Utility of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Predicting Prostate Biopsy Pathology.
    Kalapara AA, Ballok ZE, Ramdave S, O'Sullivan R, Ryan A, Konety B, Grummet JP, Frydenberg M.
    Eur Urol Oncol; 2022 Jun 04; 5(3):314-320. PubMed ID: 33741337
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Multiparametric Magnetic Resonance Imaging, 68Ga Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography, and Respective Quantitative Parameters in Detection and Localization of Clinically Significant Prostate Cancer in Intermediate- and High-Risk Group Patients: An Indian Demographic Study.
    Kubihal V, Sharma S, Kumar R, Seth A, Kumar R, Kaushal S, Sarangi J, Gupta R, Das CJ.
    Indian J Nucl Med; 2021 Jun 04; 36(4):362-370. PubMed ID: 35125753
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D, Lawrentschuk N, Sathianathen N, Kapoor J, Woo HH, Chalasani V, Rasiah K, van Leeuwen PJ, Tang R, Cusick T, Stricker P, Emmett L.
    BJU Int; 2020 Apr 04; 125(4):515-524. PubMed ID: 31957122
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y, Zeng N, Zhang F, Huang Y, Tian Y.
    Int J Clin Oncol; 2020 Jan 04; 25(1):175-186. PubMed ID: 31473884
    [Abstract] [Full Text] [Related]

  • 16. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Jan 04; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 17. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
    Araújo D, Gromicho A, Dias J, Bastos S, Maciel RM, Sabença A, Xambre L.
    Arch Ital Urol Androl; 2023 Dec 20; 95(4):11830. PubMed ID: 38117217
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prediction of clinically significant prostate cancer using a novel 68Ga-PSMA PET-CT and multiparametric MRI-based model.
    Cheng C, Liu J, Yi X, Yin H, Qiu D, Zhang J, Chen J, Hu J, Li H, Li M, Zu X, Tang Y, Gao X, Hu S, Cai Y.
    Transl Androl Urol; 2023 Jul 31; 12(7):1115-1126. PubMed ID: 37554522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.